A group of researchers led by Nanyang Technological University, Singapore (NTU Singapore) discovered that a cancer medicine that is currently on the market might be modified to target a subgroup of malignancies that are frequently linked with poor outcomes and lack focused therapy choices.
According to a study by the University of Pennsylvania, multiple myeloma, a type of bone marrow cancer, could be potentially treated by a first-of-its-kind drug.